 |
PDBsum entry 1uj3
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system/blood clotting
|
PDB id
|
|
|
|
1uj3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
214 a.a.
|
 |
|
|
|
|
|
|
|
217 a.a.
|
 |
|
|
|
|
|
|
|
205 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system/blood clotting
|
 |
|
Title:
|
 |
Crystal structure of a humanized fab fragment of anti-tissue-factor antibody in complex with tissue factor
|
|
Structure:
|
 |
Igg fab light chain. Chain: a. Fragment: anti-tissue-factor antibody hatr-5 fab. Engineered: yes. Igg fab heavy chain. Chain: b. Fragment: anti-tissue-factor antibody hatr-5 fab. Engineered: yes. Tissue factor.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Expression_system_taxid: 562
|
|
Biol. unit:
|
 |
Trimer (from
)
|
|
Resolution:
|
 |
|
2.10Å
|
R-factor:
|
0.196
|
R-free:
|
0.227
|
|
|
Authors:
|
 |
U.Ohto,R.Mizutani,M.Nakamura,H.Adachi,Y.Satow
|
|
Key ref:
|
 |
U.Ohto
et al.
(2004).
Crystal structure of a humanized Fab fragment of anti-tissue-factor antibody in complex with tissue factor.
J Synchrotron Radiat,
11,
105-108.
PubMed id:
|
 |
|
Date:
|
 |
|
25-Jul-03
|
Release date:
|
25-Jul-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
No UniProt id for this chain
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Synchrotron Radiat
11:105-108
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of a humanized Fab fragment of anti-tissue-factor antibody in complex with tissue factor.
|
|
U.Ohto,
R.Mizutani,
M.Nakamura,
H.Adachi,
Y.Satow.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Tissue factor (TF) is a membrane-anchored protein that initiates the extrinsic
cascade of blood coagulation. TF forms a complex with serine protease Factor
VIIa, and then activates Factor X zymogen to Factor Xa, leading to the blood
coagulation. Humanized anti-TF antibody hATR-5 strongly inhibits TF-initiated
blood coagulation, and is of potential use for various thrombotic diseases. The
Fab fragment of antibody hATR-5 is obtained for crystallization. The crystal
structure of the complex of the Fab with extracellular domains of human TF was
determined with the molecular replacement method, and refined to an R factor of
0.196 at 2.1 A resolution. All the complementarity-determining regions (CDRs) of
the Fab are involved in interaction with the C-terminal-side extracellular
domain of TF through 19 hydrogen bonds. The interface between the Fab and TF
molecules contains 15 water molecules, and yields buried surface areas as wide
as 2000 A2. The TF surface in the interface is possibly involved in the
activation of Factor X, by forming a transient ternary complex of Factor
X-TF-Factor VIIa. Electrostatic interactions are predominantly observed between
the heavy-chain CDRs and TF. These hydrogen-bonding and electrostatic
interactions together with the wide buried areas contribute to the high affinity
of the antibody toward TF, leading to the effective inhibition of the
TF-initiated blood coagulation.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.A.Jiao,
A.B.Kelly,
U.M.Marzec,
E.Nieves,
J.Acevedo,
M.Burkhardt,
A.Edwards,
X.Y.Zhu,
P.A.Chavaillaz,
A.Wong,
J.L.Wong,
J.O.Egan,
D.Taylor,
P.R.Rhode,
and
H.C.Wong
(2010).
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
|
| |
Thromb Haemost,
103,
224-233.
|
 |
|
|
|
|
 |
N.Mackman
(2008).
Tissue-specific hemostasis: role of tissue factor.
|
| |
J Thromb Haemost,
6,
303-305.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |
| |